StockIQ.techFresenius Medical Care AG (FME.DE) Stock Analysis
Free AI-powered analysis and research for Fresenius Medical Care AG stock
Sector: Healthcare
FME.DE snapshot
Data as of 4 Nov 2026 close. Updated daily.
Fresenius Medical Care AG scores 73/100 on StockIQ's model, which reads as positive signals overall. The price is above its 200-day average and at 56% of its 52-week range, down 0.6% over the past year. Latest reported figures show a profit margin of 4.8%, return on equity of 8.5% and revenue growth of +1.4%.
What is driving the score
- RSI Neutral: +5
- Uptrend: +6
- MACD Bullish: +8
- Low P/E (12.2): +10
- Weak Profit Margin (4.8%): -8
- Weak Liquidity (1.07 Current Ratio): -5
- Low P/B (0.86): +5
- Above MA200: +4
- Underperforming (-0.6% over 1 year): -5
- High Volume (1.8x): +3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full FME.DE report
Fresenius Medical Care AG (FME.DE) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze FME.DE Now →📰 Latest Update
What Fresenius Medical Care AG & Co. KGaA (FMS) Said on Its Q3 Earnings Call
Wed, November 4, 2026 at 6:14 AM UTC 2 min read
Fresenius Medical Care AG & Co. KGaA (FMS) reported stable third-quarter revenue but a 6% decline in operating income due to reimbursement pressures and inflation. The company is advancing its U.S. rollout of high-volume hemodiafiltration technology while executing a share repurchase program, and it expects to achieve €250 million in sustainable savings from its FME25+ transformation initiative. Management has narrowed its 2026 operating-income outlook, anticipating ongoing challenges in the reimbursement environment.